Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.

Shao L, Hou W, Scharping NE, Vendetti FP, Srivastava R, Roy CN, Menk AV, Wang Y, Chauvin JM, Karukonda P, Thorne SH, Hornung V, Zarour HM, Bakkenist CJ, Delgoffe GM, Sarkar SN.

Cancer Immunol Res. 2019 Aug;7(8):1258-1266. doi: 10.1158/2326-6066.CIR-18-0711. Epub 2019 Jun 25.

PMID:
31239318
2.

Oligoadenylate-Synthetase-Family Protein OASL Inhibits Activity of the DNA Sensor cGAS during DNA Virus Infection to Limit Interferon Production.

Ghosh A, Shao L, Sampath P, Zhao B, Patel NV, Zhu J, Behl B, Parise RA, Beumer JH, O'Sullivan RJ, DeLuca NA, Thorne SH, Rathinam VAK, Li P, Sarkar SN.

Immunity. 2019 Jan 15;50(1):51-63.e5. doi: 10.1016/j.immuni.2018.12.013. Epub 2019 Jan 8.

PMID:
30635239
3.

Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.

Moon EK, Wang LS, Bekdache K, Lynn RC, Lo A, Thorne SH, Albelda SM.

Oncoimmunology. 2018 Jan 9;7(3):e1395997. doi: 10.1080/2162402X.2017.1395997. eCollection 2018.

4.

Oncolytic Virotherapy and the Tumor Microenvironment.

Berkey SE, Thorne SH, Bartlett DL.

Adv Exp Med Biol. 2017;1036:157-172. doi: 10.1007/978-3-319-67577-0_11. Review.

PMID:
29275471
5.

Is the immune response a friend or foe for viral therapy of glioma?

Okada H, Thorne SH.

Neuro Oncol. 2017 Jul 1;19(7):882-883. doi: 10.1093/neuonc/nox082. No abstract available.

6.

Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.

Hou W, Sampath P, Rojas JJ, Thorne SH.

Cancer Cell. 2016 Jul 11;30(1):108-119. doi: 10.1016/j.ccell.2016.05.012. Epub 2016 Jun 30.

7.

Noninvasive Imaging of Fluorescent Reporters in Small Rodent Models Using Fluorescence Molecular Tomography.

Hou W, Thorne SH.

Methods Mol Biol. 2016;1444:67-72. doi: 10.1007/978-1-4939-3721-9_7.

PMID:
27283418
8.

Virus fuels NK cell killing of leukemia.

Thorne SH.

Blood. 2016 May 26;127(21):2509. doi: 10.1182/blood-2016-03-704247. No abstract available.

9.

Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown.

Kim SH, Hahm ER, Arlotti JA, Samanta SK, Moura MB, Thorne SH, Shuai Y, Anderson CJ, White AG, Lokshin A, Lee J, Singh SV.

Breast Cancer Res Treat. 2016 May;157(1):41-54. doi: 10.1007/s10549-016-3795-y. Epub 2016 Apr 21.

10.

Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies.

Rojas JJ, Sampath P, Bonilla B, Ashley A, Hou W, Byrd D, Thorne SH.

Cell Rep. 2016 Apr 12;15(2):264-73. doi: 10.1016/j.celrep.2016.03.017. Epub 2016 Mar 31.

11.

Adding STING to the Tale of Oncolytic Virotherapy.

Thorne SH.

Trends Cancer. 2016 Feb 1;2(2):67-68.

12.

Fluoromodule-based reporter/probes designed for in vivo fluorescence imaging.

Zhang M, Chakraborty SK, Sampath P, Rojas JJ, Hou W, Saurabh S, Thorne SH, Bruchez MP, Waggoner AS.

J Clin Invest. 2015 Oct 1;125(10):3915-27. doi: 10.1172/JCI81086. Epub 2015 Sep 8.

13.

Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma.

Liu J, Li F, Ping Y, Wang L, Chen X, Wang D, Cao L, Zhao S, Li B, Kalinski P, Thorne SH, Zhang B, Zhang Y.

Oncotarget. 2015 Sep 22;6(28):24978-89. doi: 10.18632/oncotarget.4617.

14.

CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma.

Liu JY, Li F, Wang LP, Chen XF, Wang D, Cao L, Ping Y, Zhao S, Li B, Thorne SH, Zhang B, Kalinski P, Zhang Y.

Br J Cancer. 2015 Sep 1;113(5):747-55. doi: 10.1038/bjc.2015.290. Epub 2015 Aug 18.

15.

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.

Rojas JJ, Sampath P, Hou W, Thorne SH.

Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009. Epub 2015 Jul 17.

16.

In vivo inflammation imaging using a CB2R-targeted near infrared fluorescent probe.

Zhang S, Shao P, Ling X, Yang L, Hou W, Thorne SH, Beaino W, Anderson CJ, Ding Y, Bai M.

Am J Nucl Med Mol Imaging. 2015 Feb 15;5(3):246-58. eCollection 2015.

17.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

18.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.

PMID:
25894825
19.

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.

Sampath P, Thorne SH.

Oncolytic Virother. 2015 Jun 18;4:75-82. doi: 10.2147/OV.S54738. eCollection 2015. Review.

20.

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL.

Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8.

21.

Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages.

Miller MR, Mandell JB, Beatty KM, Harvey SA, Rizzo MJ, Previte DM, Thorne SH, McKenna KC.

Cancer Immunol Res. 2014 Dec;2(12):1175-85. doi: 10.1158/2326-6066.CIR-14-0093-T. Epub 2014 Sep 23.

22.

Immunotherapeutic potential of oncolytic vaccinia virus.

Thorne SH.

Front Oncol. 2014 Jun 17;4:155. doi: 10.3389/fonc.2014.00155. eCollection 2014. Review.

23.

Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells.

Zou Y, Li F, Hou W, Sampath P, Zhang Y, Thorne SH.

Br J Cancer. 2014 Apr 15;110(8):1992-9. doi: 10.1038/bjc.2014.140. Epub 2014 Mar 18.

24.

Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.

Hou W, Chen H, Rojas J, Sampath P, Thorne SH.

Int J Cancer. 2014 Sep 1;135(5):1238-46. doi: 10.1002/ijc.28747. Epub 2014 Feb 18.

25.

Giving oncolytic vaccinia virus more BiTE.

Albelda SM, Thorne SH.

Mol Ther. 2014 Jan;22(1):6-8. doi: 10.1038/mt.2013.271. No abstract available.

26.

Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.

Sampath P, Thorne SH.

Oncolytic Virother. 2013 Dec 5;3:1-9. doi: 10.2147/OV.S36703. eCollection 2014. Review.

27.

The role of GM-CSF in enhancing immunotherapy of cancer.

Thorne SH.

Immunotherapy. 2013 Aug;5(8):817-9. doi: 10.2217/imt.13.65.

PMID:
23902549
28.

A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.

Thirunavukarasu P, Sathaiah M, Gorry MC, O'Malley ME, Ravindranathan R, Austin F, Thorne SH, Guo ZS, Bartlett DL.

Mol Ther. 2013 May;21(5):1024-33. doi: 10.1038/mt.2013.27. Epub 2013 Feb 26.

29.

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH.

Cancer Res. 2013 Feb 15;73(4):1265-75. doi: 10.1158/0008-5472.CAN-12-2687. Epub 2013 Feb 7.

30.

Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.

Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH.

Neoplasia. 2012 Dec;14(12):1115-21.

31.

Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination.

Tang H, Sampath P, Yan X, Thorne SH.

Gene Ther. 2013 Jul;20(7):770-8. doi: 10.1038/gt.2012.96. Epub 2013 Jan 3.

32.

Regulating cytokine function enhances safety and activity of genetic cancer therapies.

Chen H, Sampath P, Hou W, Thorne SH.

Mol Ther. 2013 Jan;21(1):167-74. doi: 10.1038/mt.2012.225. Epub 2012 Nov 13.

33.

Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH.

Mol Ther. 2013 Mar;21(3):620-8. doi: 10.1038/mt.2012.257. Epub 2012 Dec 11.

34.

Bioinspired controlled release of CCL22 recruits regulatory T cells in vivo.

Jhunjhunwala S, Raimondi G, Glowacki AJ, Hall SJ, Maskarinec D, Thorne SH, Thomson AW, Little SR.

Adv Mater. 2012 Sep 11;24(35):4735-8. doi: 10.1002/adma.201202513. Epub 2012 Jul 23. No abstract available.

35.

Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.

Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH.

Oncoimmunology. 2012 Jul 1;1(4):448-457.

36.

Theranostic potential of oncolytic vaccinia virus.

Rojas JJ, Thorne SH.

Theranostics. 2012;2(4):363-73. doi: 10.7150/thno.3724. Epub 2012 Apr 5.

37.

High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases.

Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A.

Hepatology. 2012 Jun;55(6):1863-75. doi: 10.1002/hep.25572.

38.

Practical Methods for Molecular In Vivo Optical Imaging.

Chen H, Thorne SH.

Curr Protoc Cytom. 2012;59(1224):12.24.1-12.24.11.

39.

Differential biodistribution of oncolytic poxvirus administered systemically in an autochthonous model of hepatocellular carcinoma.

Baril P, Touchefeu Y, Cany J, Cherel Y, Thorne SH, Tran L, Conchon S, Vassaux G.

J Gene Med. 2011 Dec;13(12):692-701. doi: 10.1002/jgm.1624.

PMID:
22028274
40.

Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Wang LC, Lynn RC, Cheng G, Alexander E, Kapoor V, Moon EK, Sun J, Fridlender ZG, Isaacs SN, Thorne SH, Albelda SM.

Mol Ther. 2012 Apr;20(4):736-48. doi: 10.1038/mt.2011.228. Epub 2011 Oct 18.

41.

Next-generation oncolytic vaccinia vectors.

Thorne SH.

Methods Mol Biol. 2012;797:205-15. doi: 10.1007/978-1-61779-340-0_14.

PMID:
21948478
42.

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Breitbach CJ, Thorne SH, Bell JC, Kirn DH.

Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72. Review.

PMID:
21740365
43.

Immunotherapeutic potential of oncolytic vaccinia virus.

Thorne SH.

Immunol Res. 2011 Aug;50(2-3):286-93. doi: 10.1007/s12026-011-8211-4. Review.

PMID:
21717084
44.

Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer.

Huang B, Sikorski R, Sampath P, Thorne SH.

J Immunother. 2011 Apr;34(3):289-96. doi: 10.1097/CJI.0b013e31820e1b0d.

45.

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL.

Mol Ther. 2011 Apr;19(4):650-7. doi: 10.1038/mt.2010.312. Epub 2011 Jan 25.

46.

Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.

Reeves PM, Smith SK, Olson VA, Thorne SH, Bornmann W, Damon IK, Kalman D.

J Virol. 2011 Jan;85(1):21-31. doi: 10.1128/JVI.01814-10. Epub 2010 Oct 20.

47.

Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells.

Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, Felsher DW, Thorne SH.

Cancer Res. 2010 Dec 1;70(23):9837-45. doi: 10.1158/0008-5472.CAN-10-2650. Epub 2010 Oct 8.

48.

Sustained inhibition of PKCα reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model.

Kim J, Thorne SH, Sun L, Huang B, Mochly-Rosen D.

Oncogene. 2011 Jan 20;30(3):323-33. doi: 10.1038/onc.2010.415. Epub 2010 Sep 20.

49.

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

Huang B, Sikorski R, Kirn DH, Thorne SH.

Gene Ther. 2011 Feb;18(2):164-72. doi: 10.1038/gt.2010.121. Epub 2010 Aug 26.

PMID:
20739958
50.

Alternate mechanisms of initial pattern recognition drive differential immune responses to related poxviruses.

O'Gorman WE, Sampath P, Simonds EF, Sikorski R, O'Malley M, Krutzik PO, Chen H, Panchanathan V, Chaudhri G, Karupiah G, Lewis DB, Thorne SH, Nolan GP.

Cell Host Microbe. 2010 Aug 19;8(2):174-85. doi: 10.1016/j.chom.2010.07.008.

Supplemental Content

Loading ...
Support Center